Background
==========

According to the World Health Organization (WHO), tuberculosis (TB) remains a global public health concern \[[@b1-medscimonit-21-2064]\]. In China in particular, the morbidity associated with active TB has doubled while TB-associated mortality has increased 7-fold over the past decade \[[@b2-medscimonit-21-2064],[@b3-medscimonit-21-2064]\]. Nearly all primary TB patients present with pulmonary infiltrates along with tubercular lymphadenitis (TBLA), and a substantial proportion of patients with other types of pulmonary TB also present with TBLA \[[@b4-medscimonit-21-2064],[@b5-medscimonit-21-2064]\].

Although pulmonary TB can be easily diagnosed through sputum examination for acid-fast bacilli (AFB), by smear, or by culturing for *Mycobacterium tuberculosis*, such methods are not effective for the diagnosis of TBLA. Owing to its non-specific clinical and radiographic presentation, the diagnosis of mediastinal and hilar TBLA can be challenging \[[@b6-medscimonit-21-2064]\]. Moreover, imaging by chest computed tomography (CT) scanning often cannot detect changes soon after TBLA treatment, leading to uncertainty regarding treatment strategy. To address this challenge, the development of alternative diagnostic approaches to TBLA is essential.

Since its introduction in 2004, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has emerged as a minimally-invasive approach to sampling mediastinal and hilar lymph nodes \[[@b7-medscimonit-21-2064]\]. Although EBUS-TBNA was primarily developed to diagnose and stage lung cancer \[[@b8-medscimonit-21-2064]\], it has since been applied to the diagnosis of lymphoma \[[@b9-medscimonit-21-2064]\], TB \[[@b10-medscimonit-21-2064]\], and sarcoidosis \[[@b11-medscimonit-21-2064]\]. Previous meta-analyses have demonstrated the diagnostic efficacy of EBUS-TBNA in lung cancer and sarcoidosis \[[@b12-medscimonit-21-2064],[@b13-medscimonit-21-2064]\]; however, we have found no previously published systematic reviews or meta-analyses concerning the diagnostic efficacy of EBUS-TBNA in mediastinal TBLA. Therefore, we performed a systematic review and meta-analysis to explore the diagnostic value of EBUS-TBNA in patients with mediastinal TBLA.

Material and Methods
====================

Ethics Statement
----------------

This study was conducted in compliance with the Ethics Statement of the First Affiliated Hospital of Bengbu Medical College (Bengbu, China).

Search strategy
---------------

A comprehensive search strategy was independently applied by 2 authors (WL and TZ) to search 3 computer databases (PubMed, EMBASE, and Sinoced) for relevant studies published between January 1, 2002 and April 1, 2014 using the following search term combinations: (i) (EBUS OR "EBUS TBNA" OR TBNA OR "endobronchial ultrasound" OR "endobronchial ultrasonography" OR "endobronchial ultrasound-guided" OR "endoscopic ultrasound" OR "transbronchial needle aspiration") AND tuberculosis; and (ii) (EBUS OR "endobronchial ultrasound" OR "endobronchial ultrasonography" OR "endobronchial ultrasound-guided" OR "endoscopic ultrasound") AND (TBNA OR "transbronchial needle aspiration").

Study selection
---------------

All records from the database search were imported into Endnote to eliminate duplicate records. The remaining records were screened by title and abstract to capture all relevant studies. Studies were eligible for inclusion if they reported the diagnostic yield of convex probe EBUS-TBNA in patients with clinical suspicion of mediastinal TBLA. The full text of each article meeting the inclusion criteria was obtained and reviewed. We excluded the following studies: (i) abstracts, editorials, reviews, letters, and case reports; (ii) studies reporting the diagnostic value of TBNA or endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) or radial probe EBUS-TBNA in TB; (iii) studies describing EBUS-TBNA in fewer than 10 patients with mediastinal TBLA; and (iv) studies in which the number of patients with a final diagnosis of mediastinal TBLA (i.e., pathology displaying granulomatous inflammation with clinical manifestations of TB) was not reported. Any disagreement was resolved by discussion between the authors.

Data extraction
---------------

We extracted and recorded the following data from all eligible studies**:** publication details (authors, publication year, geographic location, and other citation details); study design (prospective or retrospective); size of lymph nodes by chest CT; type of sedation; diameter of EBUS-TBNA needle; stations sampled; size of the lymph nodes on EBUS and number of lymph nodes passed made through EBUS; availability of rapid on-site evaluation (ROSE); evidence of microbiology; diagnostic yield of EBUS-TBNA in mediastinal TBLA as the percentage of the diagnosis of mediastinal TBLA by EBUS-TBNA in the patients with confirmed mediastinal TBLA; and complications associated with the procedure.

Assessment of study quality
---------------------------

The QualSyst tool \[[@b14-medscimonit-21-2064]\] was used to assess the quality and validity of each article included in the meta-analysis. This tool consists of 10 questions scored from zero to 2 with a maximum total score of 20. Each study was independently evaluated by the 2 authors for the stated criteria.

Statistical analysis
--------------------

All calculations were performed using STATA version 9.0 (Stata Corp., College Station, TX, USA). We calculated the 95% CI for each study in order to calculate the diagnostic yield of EBUS-TBNA in mediastinal TBLA and used the data to derive a pooled 95% CI through back-transformation of the weighted mean of the transformed proportions using DerSimonian weights for the random-effects model \[[@b15-medscimonit-21-2064]\] in the presence of significant heterogeneity. Chi-square and I^2^ testing were used to assess heterogeneity of study outcomes. An I^2^ value of greater than 50% or a p-value of less than 0.10 was deemed to indicate the presence of significant statistical heterogeneity \[[@b16-medscimonit-21-2064],[@b17-medscimonit-21-2064]\]. We also performed several subgroup analyses: geographic location (Asian *vs.* European), research design (prospective *vs.* retrospective), employing ROSE *vs.* not, anesthetic type (conscious sedation *vs.* intravenous), the use of microbiological assessment, the use of smear *vs.* culture, and by number of lymph node passes (\<3 *vs.* ≥3). The presence of publication bias was evaluated using funnel plots \[[@b18-medscimonit-21-2064]\], Egger's test \[[@b19-medscimonit-21-2064]\], and Begg's test \[[@b20-medscimonit-21-2064]\] with a p-value of less than 0.05 indicating significant publication bias.

Results
=======

Characteristics of included studies
-----------------------------------

The database search yielded 14 studies consisting of 684 patients with mediastinal TBLA \[[@b10-medscimonit-21-2064],[@b21-medscimonit-21-2064]--[@b33-medscimonit-21-2064]\]. The full details of these included studies are shown in [Table 1](#t1-medscimonit-21-2064){ref-type="table"}. The quality of the included studies was generally good with the median (IQR) score of 18 ([Table 2](#t2-medscimonit-21-2064){ref-type="table"}). Of the 14 included studies, 7 were prospective \[[@b10-medscimonit-21-2064],[@b21-medscimonit-21-2064],[@b23-medscimonit-21-2064],[@b26-medscimonit-21-2064],[@b27-medscimonit-21-2064],[@b29-medscimonit-21-2064],[@b33-medscimonit-21-2064]\], and 7 were retrospective \[[@b22-medscimonit-21-2064],[@b24-medscimonit-21-2064],[@b25-medscimonit-21-2064],[@b28-medscimonit-21-2064],[@b30-medscimonit-21-2064]--[@b32-medscimonit-21-2064]\]. A total of 11 patients presented with isoniazid-resistant TB \[[@b25-medscimonit-21-2064],[@b26-medscimonit-21-2064],[@b31-medscimonit-21-2064]\], and 25 patients presented with human immunodeficiency virus (HIV)-related TB \[[@b25-medscimonit-21-2064],[@b33-medscimonit-21-2064]\]. Five studies used conscious sedation with midazolam \[[@b10-medscimonit-21-2064],[@b21-medscimonit-21-2064],[@b23-medscimonit-21-2064],[@b28-medscimonit-21-2064],[@b29-medscimonit-21-2064]\], while 8 studies used intravenous anesthesia \[[@b22-medscimonit-21-2064],[@b24-medscimonit-21-2064]--[@b27-medscimonit-21-2064],[@b30-medscimonit-21-2064],[@b31-medscimonit-21-2064],[@b33-medscimonit-21-2064]\] with fentanyl or propofol to assist the anesthesia and lidocaine as the topical throat anesthetic ([Figure 1](#f1-medscimonit-21-2064){ref-type="fig"}). The 1 remaining study could not provide this information \[[@b32-medscimonit-21-2064]\].

The majority of studies sampled the paratracheal, subcarinal, hilar, and interlobar lymph nodes (stations 2, 4, 7, 10, and 11). Findings on lymph node size, number of lymph nodes aspirated, number of passes of lymph nodes, the use of ROSE, and the availability of microbiological data are shown on [Table 3](#t3-medscimonit-21-2064){ref-type="table"}. Eight studies employed additional ROSE \[[@b22-medscimonit-21-2064],[@b24-medscimonit-21-2064],[@b25-medscimonit-21-2064],[@b27-medscimonit-21-2064],[@b30-medscimonit-21-2064]--[@b33-medscimonit-21-2064]\] (with only a portion of patients employed in 1 study \[[@b25-medscimonit-21-2064]\]), and 9 studies employed microbiologic evidence for diagnosis by either culture or smear \[[@b10-medscimonit-21-2064],[@b23-medscimonit-21-2064],[@b25-medscimonit-21-2064],[@b26-medscimonit-21-2064],[@b29-medscimonit-21-2064]--[@b33-medscimonit-21-2064]\]. However, in 2 studies \[[@b23-medscimonit-21-2064],[@b29-medscimonit-21-2064]\], the culture/smear data provided unclear findings. By the random-effects model, the overall culture positive rate was 54% \[[@b10-medscimonit-21-2064],[@b25-medscimonit-21-2064],[@b26-medscimonit-21-2064],[@b31-medscimonit-21-2064]--[@b33-medscimonit-21-2064]\], and the sample smear positive rate was 30% \[[@b10-medscimonit-21-2064],[@b25-medscimonit-21-2064],[@b30-medscimonit-21-2064]--[@b33-medscimonit-21-2064]\]. The positive rate of culture was significantly higher than that of the smear (p\<0.05).

Diagnostic yield
----------------

In our results, the pooled diagnostic yield of EBUS-TBNA for mediastinal TBLA was 80% (95% CI, 74--86%) as calculated by the random-effects model ([Figure 2](#f2-medscimonit-21-2064){ref-type="fig"}). There was evidence of significant heterogeneity (I^2^=77.9%) and significant publication bias (Begg's test p=0.05 and Egger's test p=0.02).

According to our subgroup analyses ([Table 4](#t4-medscimonit-21-2064){ref-type="table"}), the diagnostic yield was significantly different in Asian *vs.* European (UK) studies, retrospective *vs.* prospective studies, those employing ROSE *vs.* not, those employing different anesthetic types, and those employing smear *vs.* culture. However, the use of microbiological assessment and the number of lymph node passes did not have a significant effect on the diagnostic yield.

Complications
-------------

Only 15 minor complications (1 case of bronchospasm, 1 panic attack, 1 case of bacteremia, 6 cases of transient hypoxia, 4 occurrences of self-limiting bleeding, and 2 occurrences of fever) were reported in the 684 patients.

Discussion
==========

Mediastinoscopy remains the criterion standard in the diagnosis and staging of enlarged mediastinal lymph nodes and has been preferred over the more invasive conventional TBNA and endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) (which cannot access the right paratracheal and hilar nodes \[[@b34-medscimonit-21-2064]\]) for the diagnosis of mediastinal lymphadenopathy. However, mediastinoscopy is invasive, costly, requires general anesthesia, and is associated with a 2% morbidity risk and 0.08% mortality risk \[[@b35-medscimonit-21-2064],[@b36-medscimonit-21-2064]\]. Moreover, mediastinoscopic sampling of mediastinal lesions can be difficult owing to their adjacency to many vital structures, and posterior-lower carinal and hilar nodes stations are typically inaccessible by mediastinoscopy \[[@b37-medscimonit-21-2064]\].

Although conventional TBNA can produce superior diagnostic yields over mediastinoscopy, complication rates for conventional TBNA are high since imaging of needle placement is not possible \[[@b38-medscimonit-21-2064]\]. Therefore, the utility and safety of conventional TBNA can be improved under EBUS guidance. This EBUS-TBNA technique allows for the performance of needle aspiration biopsy under real-time ultrasound monitoring, which can clearly show the relationship between blood vessels, lymph nodes, and space-occupying lesions in the mediastinum \[[@b39-medscimonit-21-2064]\]. As a result, EBUS-TBNA provides an efficacious and safe alternative in patients with mediastinal TBLA \[[@b11-medscimonit-21-2064]--[@b13-medscimonit-21-2064]\] and can be performed under conscious intravenous sedation \[[@b40-medscimonit-21-2064]\]. EBUS-TBNA has been shown to have significantly better safety and accuracy compared to conventional TBNA \[[@b41-medscimonit-21-2064],[@b42-medscimonit-21-2064]\]. In agreement with these previous findings, this meta-analysis reveals a strong overall diagnostic yield (80%) for EBUS-TBNA in detecting mediastinal TBLA. These findings suggest that EBUS-TBNA can be used as an initial diagnostic tool for mediastinal TBLA.

Although tuberculin skin testing, IFN-γ release assays with *M. tuberculosis* antigens, and recombinant *M. tuberculosis* early secreted antigenic target 6-kDa protein (ESAT-6) skin testing can be used to detect the presence of a TB infection \[[@b43-medscimonit-21-2064]--[@b45-medscimonit-21-2064]\], a definitive TB diagnosis can only be established with a *M. tuberculosis-*positive culture or smear. Although sputum examination has been useful in diagnosing active pulmonary TB, about half of suspected patients are unable to produce sputum, and even if sputum is produced, acid-fast bacilli (AFB) are often not found by repeated examination of direct smears \[[@b46-medscimonit-21-2064]\]. In particular, TB patients with isolated mediastinal lymphadenopathy display particularly low culture yields by sputum culture and bronchoscopy \[[@b47-medscimonit-21-2064]\]. With respect to EBUS-TBNA, Navani et al. \[[@b25-medscimonit-21-2064]\] reported a culture rate of 47% in 146 TBLA patients by EBUS-TBNA, which was similar to culture rates for mediastinoscopy \[[@b48-medscimonit-21-2064]\], TBNA without EBUS \[[@b49-medscimonit-21-2064]\], and EUS-FNA \[[@b50-medscimonit-21-2064]\]. The poor culture rates in mediastinal TBLA may be due to the scarcity of acid-fast bacilli in the lymph node, lack of suitable cellular material in samples obtained from necrotic tissue, and/or technical challenges in culturing *M. tuberculosis*. In this meta-analysis, we found that the culture positive rate (54%) was significantly higher than the sample smear positive rate (30%). Our microbiological findings support the same conclusions as previous studies \[[@b51-medscimonit-21-2064],[@b52-medscimonit-21-2064]\], but 1 included study \[[@b33-medscimonit-21-2064]\] reported a culture positivity rate approaching 99% (84/85), which may be attributable to differing operator experience/skill, lymph node size, lymph node location, sampling capacity, and/or bacillary loads in the sampled lymph nodes.

We conducted several subgroup analyses to determine factors that may affect the diagnostic yield for EBUS-TBNA in detecting mediastinal TBLA. Notably, our subgroup analyses revealed that neither microbiological assessment nor the use of more or less than 3 lymph node passes significantly affected the diagnostic yield of EBUS-TBNA in detecting mediastinal TBLA. This finding contradicts the conclusion of Yarmus et al. \[[@b53-medscimonit-21-2064]\], which may be attributable to differences in operator experience and skill levels, the heterogeneity in bacillary load of *M. tuberculosis* in aspirated lymph nodes, and the skills for culturing the *M. tuberculosis*.

The rising incidence of HIV-related TB poses a clinical challenge, as it is associated with smear-negative pulmonary TB \[[@b54-medscimonit-21-2064],[@b55-medscimonit-21-2064]\]. Smear-negative HIV-related TB displays an increased mortality compared to smear-positive TB \[[@b54-medscimonit-21-2064],[@b56-medscimonit-21-2064]\], which may be related to misdiagnoses and treatment delays \[[@b57-medscimonit-21-2064]\]. For instance, a recent study \[[@b58-medscimonit-21-2064]\] in culture-confirmed TB patients reported that the positive predictive value of an AFB smear-positive respiratory specimen is significantly inferior in HIV-seropositive patients compared to HIV-uninfected patients (p\<0.001). In this meta-analysis, 25 patients were infected with HIV -- the culture was positive in 6 of these patients, while only 1 smear was positive. Therefore, further studies are required to assess the diagnostic utility of EBUS-TBNA in HIV-infected individuals.

The major limitation of this meta-analysis is the significant heterogeneity between the included studies. This can be broadly segregated into clinical heterogeneity (i.e., variability in the participants, interventions, and outcomes), methodological heterogeneity (i.e., variations in trial design and quality), and statistical heterogeneity (i.e., variability in the treatment effects being evaluated in different trials). Since heterogeneity is a source of variability among the included studies, a random-effects model was used here to minimize these effects. Moreover, several subgroup analyses were performed to explore the sources of heterogeneity. These analyses revealed significant differences in Asian *vs.* European (UK) studies, retrospective *vs.* prospective studies, those employing ROSE *vs.* not, those employing different anesthetic types, and those employing smear *vs.* culture -- these factors may contribute to the observed statistical heterogeneity. In addition, we detected significant publication bias, which may have also contributed to the observed heterogeneity. The inclusion criteria, which may have limited certain article types and languages, may have contributed to the observed publication bias.

Conclusions
===========

EBUS-TBNA shows a strong overall diagnostic yield (80%) for EBUS-TBNA in detecting mediastinal TBLA. These findings suggest that EBUS-TBNA can be used as an initial diagnostic tool for mediastinal TBLA. Based on our subgroup analyses, the use of ROSE, culturing, and intravenous anesthesia in prospective studies should result in superior diagnostic yields for EBUS-TBNA in detecting mediastinal TBLA.
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###### 

Characteristics of included studies.

  Author (year)      Country   Study design    Age (in years)   Participants (n)   TB diagnosis (n)   HIV+
  ------------------ --------- --------------- ---------------- ------------------ ------------------ ------
  Caglayan (2011)    Turkey    Prospective     19--81 (range)   19                 16                 NA
  Hu (2011)          China     Retrospective   24--84 (range)   10                 5                  NA
  Cetinkaya (2011)   Turkey    Prospective     50.2 (mean)      48                 38                 NA
  Zhao (2012)        China     Retrospective   60.4 (mean)      11                 10                 NA
  Navani (2012)      UK        Retrospective   18--86 (range)   156                146                17
  Navani (2012)      UK        Prospective     42 (median)      28                 26                 NA
  Gu (2012)          China     Prospective     16--82 (range)   124                105                NA
  Luo (2013)         China     Retrospective   51.7 (mean)      13                 9                  NA
  Sun (2013)         China     Prospective     49 (median)      36                 35                 NA
  Kuo (2013)         China     Prospective     25--91 (range)   10                 7                  NA
  Xie (2013)         China     Retrospective   47.7 (mean)      38                 34                 NA
  Ren (2013)         China     Retrospective   \>18             65                 48                 NO
  Kaur (2013)        India     Retrospective   NA               27                 13                 NO
  Dhasmana (2014)    UK        Prospective     65.5 (median)    99                 85                 8

###### 

QualSyst quality assessment of the included studies.

  Item                                                         Caglayan (2011)   Hu (2011)   Cetinkaya (2011)   Zhao (2012)   Navani (2012)   Navani (2012)   Gu (2012)   Luo (2013)   Sun (2013)   Kuo (2013)   Xie (2013)   Ren (2013)   Kaur (2013)   Dhasmana (2014)
  ------------------------------------------------------------ ----------------- ----------- ------------------ ------------- --------------- --------------- ----------- ------------ ------------ ------------ ------------ ------------ ------------- -----------------
  Question/objective sufficiently described?                   2                 2           2                  2             2               2               2           2            2            2            2            2            2             2
  Study design evident and appropriate?                        2                 2           2                  2             2               2               2           2            2            2            2            2            2             2
  Context for the study clear?                                 2                 2           2                  2             2               2               2           2            2            2            2            2            2             2
  Connection to a wider body of knowledge?                     2                 2           1                  2             2               2               1           1            1            2            1            1            1             2
  Sampling strategy described, relevant, and justified?        2                 1           2                  2             2               2               2           2            2            2            2            2            2             2
  Data collection methods clearly described?                   2                 1           2                  1             2               2               1           1            2            2            1            2            2             2
  Data analysis clearly described?                             1                 2           1                  2             1               1               2           2            2            1            2            2            2             1
  Use of verification procedure(s) to establish credibility?   2                 2           2                  2             1               2               2           2            2            1            2            2            1             1
  Conclusions supported by the results?                        2                 2           2                  2             2               2               2           2            2            2            2            2            2             2
  Reflexivity of the account?                                  1                 2           2                  2             2               2               1           1            2            2            2            2            1             2
  **Total score**                                              **18**            **18**      **18**             **19**        **18**          **19**          **17**      **17**       **19**       **18**       **18**       **19**       **17**        **18**

###### 

EBUS-TBNA details for included studies.

  Author (year)      Nodal size by CT (mm)   Anesthesia           Stations examined   Nodal short axis on EBUS (mm)                     Aspirations     Roes                 Microbiology (smear or culture)   PCR            BAL            Needle gauge
  ------------------ ----------------------- -------------------- ------------------- ------------------------------------------------- --------------- -------------------- --------------------------------- -------------- -------------- --------------
  Caglayan (2011)    \>10                    Conscious sedation   2,4,7,10,11         19.6 (mean)                                       1.71 (mean)     No                   No                                No             No             22G
  Hu (2011)          NA                      General anesthesia   NA                  NA                                                NA              Yes                  NA                                No             No             22G
  Cetinkaya (2011)   \>10                    Conscious sedation   4,7,10              NA                                                2.6 (mean)      No                   5 (unknown Species)               No             No             22G
  Zhao (2012)        \>10                    General anesthesia   NA                  NA                                                ≥3              Yes                  No                                No             No             22G
  Navani (2012)      NA                      General anesthesia   2,4,7,10,11         22 (mean)                                         1.28 (mean)     Yes (only portion)   74/156                            No             No             22G or 21G
  Navani (2012)      NA                      General anesthesia   2,4,7               23 (mean)                                         4               No                   unknown, 11/26                    No             No             22G or 21G
  Gu (2012)          \>10                    General anesthesia   2,3,4,7,10,11,12    NA                                                1.95            Yes                  No                                No             No             22G
  Luo (2013)         NA                      Conscious sedation   2,3,4,7,10,11,12    22.1 (mean)                                       3.5             No                   No                                No             No             22G
  Sun (2013)         \>10                    Conscious sedation   2,4,7,10,11,12      20.1 (mean)                                       2.91            No                   8/35, 17/32                       No             No             22G
  Kuo (2013)         \>10                    Conscious sedation   2,4,7,10,11         Symptomatic (23.8±6.4); asymptomatic (18.9±8.3)   ≥3              No                   4 (unknown species)               No             Yes            22G
  Xie (2013)         ≥10                     General anesthesia   2,4,7,10,11         18.7 (mean)                                       3.5             Yes                  21/34                             Yes (only 9)   No             22G
  Ren (2013)         \>10                    General anesthesia   7,4R                15 (median)                                       NA              Yes                  11/20,17/20                       No             Yes            22G
  Kaur (2013)        NA                      NA                   NA                  NA                                                NA              Yes                  8/13,5/36                         No             Yes            NA
  Dhasmana (2014)    NA                      General anesthesia   2,4,7,10,11         NA                                                4--14 (range)   Yes                  14/85,84/85                       Yes            Yes (only 2)   22G

###### 

Subgroup analysis of included studies.

  Item                        Studies (n)   Participants (n)   Diagnostic yield   Lower 95% CI limit   Upper 95% CI limit   P-value   I^2^ (%)
  --------------------------- ------------- ------------------ ------------------ -------------------- -------------------- --------- ----------
  Geography                                                                                                                           
   Asian                      11            401                75                 68                   83                   \<0.05    68.3
   European (UK)              3             283                91                 86                   96                   46.8      
  Research design                                                                                                                     
   Prospective                7             364                82                 75                   89                   \<0.05    60.0
   Retrospective              7             320                77                 65                   89                   84.9      
  Employing ROSE                                                                                                                      
   Yes                        7             374                79                 70                   87                   \<0.05    74.7
   No                         6             154                77                 69                   89                   67.1      
  Anesthesia                                                                                                                          
   Conscious sedation         5             126                73                 64                   83                   \<0.05    34.6
   Intravenous anesthesia     8             531                86                 81                   92                   69.0      
  Employing microbiology                                                                                                              
   Yes                        8             459                79                 70                   88                   \>0.05    85.4
   No                         5             177                81                 72                   91                   39.4      
  Microbiology                                                                                                                        
   Smear                      6             377                30                 18                   42                   \<0.05    86.1
   Culture                    6             361                54                 20                   89                   98.9      
  No. of lymph nodal passes                                                                                                           
   \<3                        5             383                82                 72                   91                   \>0.05    83.6
   ≥3                         6             199                88                 83                   92                   4.5       
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